LQDA Liquidia Corporation - Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · liquidia.com

26.24USD-8.38%Mkt Cap: 2.56B $P/E: 20.46Today

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPI…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited

$56.90BUSD

TEVA

Teva Pharmaceutical Industries Limited

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB (publ)

$14.14BUSDP/E 110.6

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated

$11.25BUSD

RDY

Dr. Reddy's Laboratories Limited

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc.

$6.92BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap2.56B USD

Enterprise Value2.46B USD

Revenue (TTM)450.91M USD

Gross Profit145.08M USD

Net Income (TTM)-68.92M USD

Revenue/Share5.15 USD

Last Price26.24 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees216

CountryUS

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)20.46

P/E (Forward)11.91

PEG—

EV/EBITDA14.50

EV/Revenue5.46

P/S5.69

P/B13.08

EPS (TTM)1.39

EPS (Forward)2.40

52W Range

21.157% of range93.61

52W High93.61 USD

52W Low21.15 USD

Profitability

Gross Margin91.64%

Oper. Margin49.81%

EBITDA Margin37.65%

Profit Margin-43.53%

ROE-154.03%

ROA-21.02%

Growth

Revenue Growth1842.70%

Earnings Growth—

Cash Flow & Leverage

Operating CF-35.69M USD

CapEx (TTM)6.34M USD

FCF Margin16.48%

FCF Yield2.90%

Net Debt-101.28M USD

Net Debt/EBITDA-0.60

Balance Sheet

Debt/Equity4.42

Current Ratio2.31

Quick Ratio2.08

Book Value/Sh2.19 USD

Cash/Share3.17 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating2.3 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)49.67 USD

Upside (mean)+89.3%

Target Range30.00 USD – 72.00 USD

30.00+89.3% to mean72.00

# Analysts6

Ownership

Shares Out.89.51M

Float65.37M

Insiders9.24%

Institutions81.92%

Short Interest

Short Ratio10.8d

Short % Float17.16%

Short % Out.13.83%

Shares Short12.38M

Short (prev mo.)11.86M

Technical

SMA 5071.97 (-63.5%)

SMA 20054.20 (-51.6%)

Beta0.54

S&P 52W Chg14.58%

Avg Vol (30d)3.11M

Avg Vol (10d)6.06M

Technical Indicators

RSI (14)20.7

MACD-8.8296

MACD Signal-4.7103

MACD Hist.-4.1193

BB Upper91.62 USD

BB Middle62.47 USD

BB Lower33.33 USD

BB Width93.31%

ATR (14)6.457 USD

Vol Ratio (20d)2.51x